Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial

Mikhail Kosiborod,Pardeep S. Jhund,Kieran F. Docherty,Mirta Diez,Mark C. Petrie,Subodh Verma,José C. Nicolau,Béla Merkely,Masafumi Kitakaze,David L. DeMets,Silvio E. Inzucchi,Lars Koeber,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Scott D. Solomon,Olof Bengtsson,Daniel Lindholm,Anna Niklasson,Mikaela Sjöstrand,Anna Maria Langkilde,John J.V. McMurray

Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial

2019

Background: Goals of management in patients with heart failure and reduced ejection fraction (HFrEF) include reducing death and hospitalizations, and improving health status (symptoms, physical fun...

Keywords:

Cardiology
Quality of life
Internal medicine
Diabetes mellitus
Medicine
Ejection fraction
physical function
Dapagliflozin
Heart failure
MEDLINE
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

110

Citations